Research Journal of Biological Sciences
ISSN: Online 1993-6087ISSN: Print 1815-8846
Abstract
Solasodine rhamnosyl glycosides (SRGs) are a new class of chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation CuradermBEC5 is now available for the treatment of skin cancers. Phase 2 clinical trials with intravenous (i.v.) administration of SRGs on patients with internal cancers are currently being done. The specificity and mode of action of SRGs are vastly different than those of other traditional anti-mitotic anticancer drugs. These differences have now led to SRGs intralesion chemotherapy, a very effective, new safer, anticancer modality, resulting in rapid regression of solid tumours using 1% of the dose that is required when compared with SRGs i.v. administration. In this feasibility pilot study large external tumours of animals and man were injected intralesionally with SRGs. Results demonstrate that SRGs when injected intralesionally successfully dispose of large tumours without any clinical adverse effects and that apoptosis is the cause of cancer cell death.
How to cite this article:
Bill E. Cham . Cancer Intralesion Chemotherapy with Solasodine Rhamnosyl Glycosides.
DOI: https://doi.org/10.36478/rjbsci.2008.1008.1017
URL: https://www.makhillpublications.co/view-article/1815-8846/rjbsci.2008.1008.1017